Proteasomal Inhibition for Patients With Mis-sense Mutated Dysferlin

NCT01863004 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped insufficient enrollment rate

Conditions

Dysferlinopathy

Interventions

DRUG: Bortezomib

Sponsor

University Hospital, Basel, Switzerland